RGEN · Repligen Corp
$131.96
-5.65 (-4.10%)
At close · Jul 24
Market Cap
$7.44B
Shares
56.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$137.60
Open$144.23
Day$132.28–148.37
52W$100.99–175.77
Avg vol 30d1.1M
Short int5.8M · 10.3% float · 7.9d
Short vol76%
Last earningsJul 22, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Oct 15, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
+6%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
49%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−12%
trailing
YTD return
−16%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $130 › 200d $140 — 200d above 50d
Institutional flow
Accumulating
101 of 443 funds reported for Jun 30 · net +286.1K sh shares · +21 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.30% of float · ▼ -3.9% MoM · 7.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
443 holders — near 3-yr low, contrarian setup
Squeeze score
90
high risk · 0–100
Fundamentals
Revenue growth
+35%
Y/Y
EPS growth
+287%
Y/Y
Free cash flow
$93.9M
Valuation
P/E 145
rich
Buyback
$25.0M
authorized
Balance sheet
$23.8M
net cash
Quant / Vol
risk profile
Volatility
46%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
Total Reported Revenue
· FY 2026
Initiated
$803M – $833M
prior FY $738.26M
midpoint +10.8% Y/Y
Reported Growth
· FY 2026
Initiated
9% – 13%
Organic Growth
· FY 2026
Initiated
9% – 13%
Gross Margin
· FY 2026
Non-GAAP
Initiated
53.7% – 54.2%
Income from Operations
· FY 2026
Non-GAAP
Initiated
$124M – $132M
Operating Margin
· FY 2026
Non-GAAP
Initiated
15.4% – 15.8%
Adjusted EBITDA Margin
· FY 2026
Non-GAAP
Initiated
20.3% – 20.8%
Tax Rate on Pre-Tax Income
· FY 2026
Non-GAAP
Initiated
22% – 23%
Net Income
· FY 2026
Non-GAAP
Initiated
$111.5M – $116.5M
Earnings Per Share - Diluted
· FY 2026
Non-GAAP
Initiated
$1.97 – $2.05
Guided vs delivered
· last 1 settled
Revenue
full year 2025
guided $715M – $735M
$738.26M
Beat +1.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
+6%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
49%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $130 › 200d $140 — 200d above 50d
Institutional flow
Accumulating
101 of 443 funds reported for Jun 30 · net +286.1K sh shares · +21 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.30% of float · ▼ -3.9% MoM · 7.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
443 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $101
Now $138 · 49%
52-wk high $176
vs 200-day avg -2%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGEN
this stock
Repligen Corp
|
$7.44B | -16.0% | +35.1% | 145.0 | 10.3% |
|
ISRG
Intuitive Surgical Inc
|
$119.23B | -41.4% | +20.5% | 38.8 | 1.9% |
|
MDLN
Medline Inc.
|
$50.91B | -7.7% | +11.5% | — | 2.2% |
|
BDX
Becton Dickinson & Co
|
$43.08B | +1.6% | +8.2% | 59.4 | 3.8% |
|
ALC
Alcon Inc
|
$33.12B | -14.7% | +10.5% | — | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGEN | -7.4% | -0.6% | -12.0% | +0.9% | -16.0% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -5.7% | -1.3% | -18.4% | +2.0% | -24.3% |
Capital returns
Buyback program
· as of Dec 31, 2023
Authorized
$25.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
730272
CUSIP
759916109
13F (30d)
94 filings
94 filers
Visit website
Investor relations